Statement Of Cash Flows [Abstract]

ABIONYX Pharma - Filing #879713

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
2020-01-01 to
2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
5 822 EUR
5 822 EUR
1 886 EUR
1 886 EUR
Adjustments to reconcile profit (loss) [abstract]
Adjustments for provisions
49,000 EUR
39,000 EUR
Adjustments for share-based payments
815,000 EUR
98,000 EUR
Other adjustments for non-cash items
10,000 EUR
23,000 EUR
Cash flows from (used in) operations
4 948 EUR
2 729 EUR
Cash flows from (used in) operating activities
6 692 EUR
599,000 EUR
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities
3,000 EUR
23,000 EUR
Purchase of property, plant and equipment, classified as investing activities
166,000 EUR
103,000 EUR
Purchase of intangible assets, classified as investing activities
45,000 EUR
Cash flows from (used in) investing activities
1 338 EUR
125,000 EUR
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
4 056 EUR
1 836 EUR
Repayments of borrowings, classified as financing activities
19,000 EUR
Cash flows from (used in) financing activities
3 972 EUR
1 547 EUR
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
1 382 EUR
823,000 EUR
Cash and cash equivalents
7 935 EUR
9 154 EUR

Talk to a Data Expert

Have a question? We'll get back to you promptly.